DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies

Completed

Conditions: Breast Cancer
Lung Cancer
Rectal Cancer

First Posted Date: 2009-09-09

Last Posted Date: 2013-10-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 59

Registration Number: NCT00973440

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Observational Study of Iron Overload in Stem Cell Transplantation

Completed

Conditions: Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions: Other: No Intervention

First Posted Date: 2009-08-07

Last Posted Date: 2013-02-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT00954720

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: ketoconazole
Drug: hydrocortisone
Drug: dutasteride
Drug: lapatinib

First Posted Date: 2009-08-06

Last Posted Date: 2018-09-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 11

Registration Number: NCT00953576

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Phase 1

Completed

Conditions: Neuroendocrine Tumor
Carcinoid Tumor
Pancreatic Neuroendocrine Tumor

Interventions: Drug: Sorafenib
Drug: RAD001

First Posted Date: 2009-07-21

Last Posted Date: 2014-04-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT00942682

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Phase 2

Completed

Conditions: Thyroid Cancer

Interventions: Drug: RAD001

First Posted Date: 2009-07-10

Last Posted Date: 2021-10-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT00936858

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Mt. Sinai Medical Center, New York, New York, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: LBH589

First Posted Date: 2009-07-10

Last Posted Date: 2021-01-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 39

Registration Number: NCT00936611

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Rocky Mountain Cancer Centers, Denver, Colorado, United States

Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

Phase 3

Completed

Conditions: Hodgkin Lymphoma
Non-hodgkin Lymphoma

Interventions: Drug: Sirolimus
Drug: Methotrexate
Drug: Tacrolimus
Drug: Cyclosporine
Drug: MMF

First Posted Date: 2009-06-25

Last Posted Date: 2019-02-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 139

Registration Number: NCT00928018

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 2 locations

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Cyclophosphamide
Drug: Methotrexate

First Posted Date: 2009-06-22

Last Posted Date: 2022-01-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 55

Registration Number: NCT00925652

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 6 locations

Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Stomach Cancer
Gastric Cancer

Interventions: Drug: Bevacizumab
Drug: Cisplatin
Device: Docetaxel
Drug: Irinotecan

First Posted Date: 2009-06-02

Last Posted Date: 2022-11-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 88

Registration Number: NCT00911820

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 1 locations

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Vorinostat
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2009-05-29

Last Posted Date: 2018-09-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00910000

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy